Actively Recruiting
A Study to Access Activity and Safety With SAR445399 Compared With Placebo in Participants Aged 18 to 80 Years of Age With Non-Cystic Fibrosis Bronchiectasis
Led by Sanofi · Updated on 2026-05-13
70
Participants Needed
1
Research Sites
118 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a randomized, double-blind, placebo-controlled study to measure the reduction in mucus plug score at 24 weeks of treatment with SAR445399 compared with placebo in adult participants aged 18 to 80 years with non-cystic fibrosis bronchiectasis (NCFB).
CONDITIONS
Official Title
A Study to Access Activity and Safety With SAR445399 Compared With Placebo in Participants Aged 18 to 80 Years of Age With Non-Cystic Fibrosis Bronchiectasis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Participants must be 18 to 80 years of age inclusive, at the time of signing the informed consent
- Clinical history consistent with NCFB, such as chronic productive cough and/or recurrent respiratory infections
- Documented evidence of at least 2 PEx defined as episodes requiring a physician-prescribed course of antibiotics (oral and/or IV) for 6 days for signs and symptoms of respiratory infection within the 12 months prior to the Screening Visit
- Radiologic evidence of bronchiectasis, confirmed by a chest HRCT
- A minimum MPS of 4 (out of maximum 18) on chest HRCT performed before Baseline Visit
- Current sputum production with a documented history of chronic expectoration lasting 6 months within the previous 12 months
- Participants must have a post-bronchodilator FEV1 630% of predicted normal value
You will not qualify if you...
- A primary diagnosis of smoking-related COPD or asthma as determined by the Investigator. Participants with comorbid smoking-related COPD may be included if bronchiectasis is confirmed as their primary diagnosis and is the predominant cause of their respiratory symptoms
- Diagnosis of ABPA or any of the allergic bronchopulmonary mycoses
- Active NTM lung infection or incomplete NTM treatment course
- Bronchiectasis due to any of the following: CF, CVID, AAT or PCD
- History of significant hemoptysis (requiring medical intervention and/or requiring blood transfusion)
- Current tobacco smokers
- Known or suspected immunosuppression, including history of invasive opportunistic infections (eg., histoplasmosis, listeriosis, coccidioidomycosis, pneumocystosis, aspergillosis), despite infection resolution, or otherwise recurrent infections of abnormal frequency, or prolonged infections suggesting an immune-compromised status, as judged by the Investigator
- Participants with active autoimmune disease or participants using immunosuppressive therapy for autoimmune disease, including but not limited to connective tissue diseases (eg., systemic lupus erythematosus, scleroderma, polymyositis, dermatomyositis, mixed connective tissue disease), rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis, Hashimoto's thyroiditis, Graves' disease, primary biliary cirrhosis, and psoriasis vulgaris
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Advanced Pulmonary Research Institute- Site Number : 8400001
Loxahatchee Groves, Florida, United States, 33470
Actively Recruiting
Research Team
T
Trial Transparency email recommended (Toll free for US & Canada)
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here